• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles IPO

Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles IPO

August 14, 2014 By Brad Perriello

Allergan-Valeant update: SEC launches Ackman probe, Allergan pays up to $588M for Liris bladder drug, Ackman dangles Pershing IPO

Hedge fund mogul William Ackman and his Pershing Square Capital Management are facing an insider trading probe by the U.S. Securities & Exchange Commission over the hostile takeover bid for Allergan (NYSE:AGN) by Pershing Square and Valeant Pharmaceuticals, according to news reports.

Ackman and Valeant have been pressing for months for a proxy vote to oust Allergan’s board and replace it with a roster of their own candidates who would approve the $43.7 billion merger. Allergan has alleged in a lawsuit that its unwanted suitors broke insider trading laws in pursuing the union.

The battle isn’t keeping either Allergan or Ackman from getting on with business. Allergan today announced a deal for Taris Biomedical’s Phase II bladder drug, Liris, that’s worth up to $588 million. And Bloomberg reported that Ackman, undaunted by the SEC investigation, dangled the possibility of an IPO for Pershing Square.

The Wall Street Journal, citing "people familiar with the matter," said today that the SEC’s civil probe "is focused on potential breaches of insider trading laws."

"The inquiry is at a relatively early stage and may not lead to any enforcement action," according to the newspaper. "Regulators often look closely at novel or unusual developments in the market, and many investigations go nowhere."

"We are confident that the trading was completely lawful," Valeant told the Journal in a prepared statement today.

The SEC investigation isn’t the only government scrutiny facing the hostile takeover. Earlier this week, the Federal Trade Commission made a 2nd request for information about Valeant’s offer.

Filed Under: Mergers & Acquisitions, News Well, Pharmaceutical, Wall Street Beat Tagged With: Allergan, Pershing Square Capital Management, Valeant Pharmaceuticals

More recent news

  • Aurora Spine begins first procedures with Aero lumbar fusion system
  • Caranx Medical surgical robot TaviPilot AI software wins FDA clearance
  • InspireMD launches carotid stent in U.S. after FDA approval
  • Neuros Medical raises $56M Series D to support nerve stim tech
  • CorWave reports first-in-human LVAD implant

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy